Supriya Lifescience Q3 FY26 Revenue at ₹206.44 Crore, Net Profit ₹49.68 Crore
Supriya Lifescience reported Q3 FY26 revenue of ₹206.44 crore and net profit of ₹49.68 crore. For the nine months ended December 31, 2025, revenue was ₹551.35 crore and net profit was ₹134.89 crore. The results were approved by the board on February 09, 2026.
The financial results show growth in quarterly performance, which is material for investors. However, the nine-month profit saw a slight decrease, tempering the overall impact.
The company reported an increase in revenue and net profit for the quarter ended December 31, 2025, compared to the same period last year, indicating positive operational performance.
Supriya Lifescience Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a total revenue from operations of ₹206.44 crore for the third quarter of fiscal year 2026, a slight increase from ₹185.65 crore in the same period last year. The net profit after tax for the quarter stood at ₹49.68 crore, up from ₹46.78 crore in the corresponding quarter of the previous fiscal year.
For the nine-month period ended December 31, 2025, the total revenue from operations was ₹551.35 crore, compared to ₹512.38 crore in the same period last year. The net profit after tax for the nine months was ₹134.89 crore, a decrease from ₹137.58 crore in the prior-year period.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors on February 09, 2026. The company also published extracts of these unaudited financial results in the Financial Express and Loksatta newspapers on February 10, 2026, in compliance with SEBI regulations.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.